modelR07AX01
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | NitricOxide | |
| ATC code: | R07AX01 | route: | inhalation |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.48 | L |
| clearance: | 90 | L/h/kg |
| other parameters in model implementation | ||
Nitric oxide is an inhaled gas approved for the treatment of hypoxic respiratory failure in neonates and infants with pulmonary hypertension. It acts as a selective pulmonary vasodilator, improving oxygenation and decreasing the need for extracorporeal membrane oxygenation. Due to its short half-life and rapid inactivation by hemoglobin, it acts locally in the pulmonary vasculature. Nitric oxide is not used orally or intravenously, and its clinical administration is limited to controlled inhalation.
Pharmacokinetics
Pharmacokinetic parameters are primarily determined in neonates and young children with pulmonary hypertension receiving inhaled nitric oxide; data derived from clinical use and PK estimates.
References
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Bjermer, L (2011). Targeting small airways, a step further in asthma management. The clinical respiratory journal 5(3) 131–135. DOI:10.1111/j.1752-699X.2011.00240.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21501394
Tamada, T, et al., & Ichinose, M (2015). Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. International journal of chronic obstructive pulmonary disease 10 2169–2176. DOI:10.2147/COPD.S88274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26491283
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)